{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.6"}]}],"title":"Week 48: Maintained response 24 weeks (n=1937)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.7"}]}],"title":"Week 96: Maintained response 24 weeks (n=1745)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.4"}]}],"title":"Week 96: Maintained response 48 weeks (n=1745)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1"}]}],"title":"Week 144: Maintained response 24 weeks (n=1615)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.1"}]}],"title":"Week 144: Maintained response 48 weeks (n=1615)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9"}]}],"title":"Week 144: Maintained response 96 weeks (n=1615)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.3"}]}],"title":"Week 192: Maintained response 24 weeks (n=1514)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.7"}]}],"title":"Week 192: Maintained response 48 weeks (n=1514)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.6"}]}],"title":"Week 192: Maintained response 96 weeks (n=1514)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5"}]}],"title":"Week 192: Maintained response 144 weeks (n=1514)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.7"}]}],"title":"Week 264: Maintained response 24 weeks (n = 1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6"}]}],"title":"Week 264: Maintained response 48 weeks (n = 1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.4"}]}],"title":"Week 264: Maintained response 96 weeks (n = 1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.7"}]}],"title":"Week 264: Maintained response 144 weeks (n = 1358)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.1"}]}],"title":"Week 264: Maintained response 192 weeks (n = 1358)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2067"}],"units":"Participants"}],"description":"A DAS-28 responder was defined as someone who met the European League Against Rheumatism \\[EULAR\\] criteria of a good or moderate response. A change of the DAS-28 score from Baseline was used to determine EULAR responses of good, moderate, or no response. For a post-baseline score ≤ 3.2, a change from baseline of \\< -1.2 was a good response, \\< -0.6 to ≥ -1.2 was a moderate response, and ≥ -0.6 was no response. For a post-baseline score \\> 3.2 to ≤ 5.1, a change from baseline of \\< -0.6 was a moderate response and ≥ -0.6 was no response. For a post-baseline score \\> 5.1, a change from baseline \\< -1.2 was a moderate response and ≥ -1.2 was no response. A good response could not be achieved for post-baseline scores \\> 3.2.","groups":[{"description":"Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.","id":"OG000","title":"Tocilizumab"}],"paramType":"NUMBER","populationDescription":"All-exposure population: All participants who entered this study and received at least 1 dose of tocilizumab in either this extension study or in a core study. Only participants with available data were included in the analysis.","timeFrame":"Baseline to Week 264","title":"Percentage of Participants Who Maintained a Disease Activity Score 28 (DAS-28) Response for 24, 48, 96, 144, and 192 Weeks at Weeks 48, 96, 144, 192, and 264","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}